Klaus Eichmüller, EU Inspector, Germany
Dr Line Lundsberg-Nielsen, NNE, Denmark
Dr Thomas Schneppe, Bayer Bitterfeld, Germany
With the publication of the Guidance for Industry “Process Validation: General Principles and Practices” 2011, the FDA requires a „Life Cycle Process” with 3 stages:
- Process Design
- Process Qualification
- Continued Process Verification
The focus is on process knowledge and process understanding. Both should be a result of development and verified in routine production. The “magic” 3 batches are not mentioned any more. What is very important nowadays is the term „scientific sound“, and explicit statistics are mentioned. Six Sigma elements (e.g. Design of Experiments, DoE) are also mentioned directly or indirectly. There is also a stage in routine production called „Continued Process Verification“.
The EU Process Validation Guidelines incl Annex 15 of the EU GMP requires in a similar way a 3-stage life cycle approach to Process Validation: Pharmaceutical development, Process Validation and Ongoing Process Verification. In Europe 3 validation approaches are possible – traditional, continuous and hybrid.
- How can the requirements be achieved?
- How fit the FDA requirements into European guidelines and vice versa?
- How can process knowledge and process understanding be demonstrated on the basis of development studies?
- When is a process valid now?
- Which parameters can be used for knowledge and understanding studies?
- How can „Continued/Ongoing Process Verification” be realised?
These questions are at the centre of this online-Course.
Since 1987 the FDA Guideline on Process Validation has been the basis for qualification and validation. Within the FDA programme “Pharmaceutical cGMPs for the 21st Century” there was an announcement for a revision of the guideline. A FDA Policy Guide of 2004 gave some hints to the new validation approach. In November 2008 the “Guidance for Industry Process Validation: General Principles and Practices” was published as a draft and came into operation in January 2011. That is now FDA’s „current thinking“. The chapter 1 of the EU GMP Guide gives hints for more emphasises on process capabilities and varieties within process validation also in Europe. EMA´s Process Validation Guidance and also the revised Annex 15 from 2015 takes a life cycle approach to Process Validation nowadays.
The addressees of the event are qualified staff charged with or responsible for validation activities, such as commissioners for validation, heads of quality assurance, department heads, etc. It also addresses members of validation teams (e.g. engineers, chemists, pharmacists, microbiologists) as well as representatives of the plant engineering industry and Consultants.
We use Webex for our live online training courses and webinars. At www.gmp-compliance.org/training/online-training-technical-information
you will find all the information you need to participate in our events and you can check if your system meets the necessary requirements to participate. If the installation of browser extensions is not possible due to your rights in the IT system, please contact your IT department. Webex is a standard nowadays and the necessary installation is fast and easy.
- The validation life cycle
FDA´s current thinking
- How the concept of Process Validation is about to change
- Ongoing changes in the Quality Management philosophy
- Real-life examples
The current EU Approach on Process Validation
- Process Validation in EU guidelines
- What has changed?
- Revision of Chapter 1 EU GMP Guide
- EMA´s Guidance Process Validation
- Annex 15 revision
- Excursion QbD
- Excursion Legacy Products
- The future of Process Validation
- Process Design
- Quality by Design, ICH Q8 and Q11
- Quality Target Product Profile
- Critical Quality Attribute
- Critical Process Parameter
- Design Space
- Control Strategy
- Continual Improvement
- Link between QbD the Control Strategy and Process Design
Systems and Tools for gaining Process Understanding and establishing the Control Strategy
- Process Understanding & the Control Strategy
- Quality Risk Management
- Process Analytical Technology
- Design of Experiments
- Process Analysers
- Multivariate Data Analysis
Case Study Process Design
- Stage 1
- Applying QbD principles to design a process for an oral solid dosage formulation
- Examples of the application of DoE and PAT
- Establishing the control strategy
Process Validation / Process Performance
- The purpose and principles of PV/PPQ
- EU’s different approaches to Process Validation
- Number of PV/PPQ batches
- Acceptance criteria
- PV/PPQ readiness
- PV/PPQ reporting and conclusion
Case Study Process Validation / Process Performance Qualification
- Stage 2.1: Designing the equipment and facility qualification programme based on the Control Strategy
- Stage 2.2: Establishing the PPQ/PV programme based on the Control Strategy
- Justifying the number of PPQ/PV batches
- Presenting and evaluating data
- Concluding the PPQ/PV activities
- Proposing a stage 3 CPV/OPV programme
Ongoing/Continued Process Verification
- EMA: Ongoing Process Verification
- FDA: Continued Process Verification
- Statistical tools
- Monitoring plan – OPV/CPV plan
- OPV/CPV for Legacy Products
Case Study Ongoing/Continued Process Verification
- Establishing the CPV/OPV programme
- Application of relevant statistics during stage 3
Case Study Ongoing Process Verification Programme for Legacy Products
- Establishing an OPV programme for Legacy Products
- Defining the relevant Statistical Metrics
- Running, evaluating and updating the Programme
Wrap-up and considerations for Process Validation in a future Industry 4.0 manufacturing environment
- How will Process Validation evolve in light of more automated and self-optimising processes
- A holistic approach to validation – covering qualification of equipment, control systems, computer systems, processes and analytical technologies and methods
- The role of the Control Strategy
Three Q&A sessions (two on day 1 and one on day 2) ensure interaction and that your questions are answered.